Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial.

ABSTRACT:

Objective

The purpose of this study was to evaluate the extended efficacy, safety, and tolerability of escitalopram relative to placebo in adolescents with major depressive disorder (MDD).

Methods

Adolescents (12-17 years) who completed an 8-week randomized, double-blind, flexible-dose, placebo-controlled, lead-in study of escitalopram 10-20 mg versus placebo could enroll in a 16-24-week, multisite extension trial; patients maintained the same lead-in randomization (escitalopram or placebo) and dosage (escitalopram 10 or 20 mg/day, or placebo) during the extension. The primary efficacy was Children's Depression Rating Scale-Revised (CDRS-R) change from the lead-in study baseline to treatment week 24 (8-week lead-in study plus 16-week extension); the secondary efficacy was Cl

SUBMITTER: Findling RL 

PROVIDER: S-EPMC3779002 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature